Umeclidinium Levels and Effects while Breastfeeding
Summary of Use during Lactation
Although no published data exist on the use of umeclidinium during breastfeeding, it produces low systemic maternal serum levels and any drug in breastmilk would not be absorbed by the infant. The risk to the breastfed infant of maternal umeclidinium inhalation is small. Breastfeeding can be continued during umeclidinium therapy.[1] Combination products such as Anoro Ellipta are acceptable for similar reasons.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Bendien SA, de Kruif MD, Feitsma H, et al. Summary of the Dutch Multidisciplinary Practice Guideline on Asthma and Pregnancy. J Allergy Clin Immunol Pract 2024;12:1751-62 [PubMed: 38513758]
Substance Identification
Substance Name
Umeclidinium
CAS Registry Number
869185-19-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Parasympatholytics
Muscarinic Antagonists
Bronchodilator Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
